Skip to content

Long-term Follow-up of a Cochlear Implant With Dexamethasone Eluting Electrode Array

Long-term Follow-up of a Cohort of Adult CI632D and CI632 Participants in the CLTD5759 CI-DEX Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06936449
Acronym
CI-DEX-LTFU
Enrollment
19
Registered
2025-04-20
Start date
2025-05-05
Completion date
2028-03-01
Last updated
2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bilateral Hearing Loss, Sensorineural Hearing Loss

Keywords

cochlear implant, dexamethasone, bilateral hearing loss, sensorineural hearing loss

Brief summary

A long-term follow-up of Cochlear's cochlear implant electrode array which passively elutes dexamethasone for a defined period of time to help reduce inflammatory responses.

Interventions

DEVICECI632D

CI632 cochlear implant with Slim Modiolar electrode including dexamethasone in the electrode within wells

DEVICECI632

CI632 cochlear implant with Slim Modiolar electrode with market approval and does not include dexamethasone

Sponsors

Cochlear
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects who completed study obligations of the CLTD5759 CI-DEX study and enrolled at a site selected for participation. * Subjects implanted with a CI632D or a CI632 cochlear implant under the CLTD5759 (NCT04750642). * Willing and able to provide written informed consent.

Exclusion criteria

* Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to participation as determined by the Investigator. * Additional disabilities that may affect the subject's participation or safety during the clinical investigation. * Unable or unwilling to comply with all the requirements of the clinical investigation as determined by the Investigator. * Currently participating, or participated within the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device.

Design outcomes

Primary

MeasureTime frame
Comparison of Monopolar (MP1+2) Impedance Measurement (kOhms) between groups obtained in the CLTD5759 (NCT04750642) study, and at the 2 through 5 years post-activation routine follow-up visits.5 years post-activation

Secondary

MeasureTime frame
Comparison of CI632D and CI632 device-related adverse events between groups from enrolment in this study through 5 years postactivation.5 years post-activation
Comparison of Four-point Impedance Measurement between groups obtained in the CLTD5759 (NCT04750642) study, and from enrolment in this study through 5 years postactivation.5 years post-activation
Comparison of low-frequency acoustic hearing between groups as measured by pure tone average thresholds over the range 125 through 500 Hz, obtained in the CLTD5759 (NCT04750642) study and from enrolment in this study through 5 years postactivation.5 years post-activation
Comparison of speech perception in quiet (CNC word scores) for the best unilateral listening condition in the implanted ear between groups obtained in the CLTD5759 (NCT04750642) study, and from enrolment in this study through 5 years postactivation.5 years post-activation
Speech perception in noise (AzBio sentence scores) for the best bilateral listening condition obtained between groups in the CLTD5759 (NCT04750642) study, and from enrolment in this study through 5 years postactivation.5 years post-activation

Countries

United States

Contacts

CONTACTPRS Specialist
cltd-prs-admin@cochlear.com+61 2 9428 6555

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 8, 2026